Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice?
Fabi A, Ciccarese M, Scagnoli S, Russillo M, Schettini F, Buono G, Lorusso V, Cannita K, Arpino G, Stani S, Palleschi M, Rossello R, Sarobba G, Fabbri A, Giampaglia M, Pellegrini P, Adamo V, Morelli F, Barberi V, Ferretti G, Catania G, Pisegna S, Cognetti F, Giannarelli D. Fabi A, et al. Among authors: morelli f. Oncology. 2021 Dec 7. doi: 10.1159/000521252. Online ahead of print. Oncology. 2021. PMID: 34875670
Treatment Sequencing and Outcome of Chronic Lymphocytic Leukemia Patients Treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Thirty-Year Single-Center Experience.
Innocenti I, Fresa A, Tomasso A, Tarnani M, De Padua L, Benintende G, Pasquale R, Galli E, Morelli F, Giannarelli D, Autore F, Laurenti L. Innocenti I, et al. Among authors: morelli f. Cancers (Basel). 2023 Nov 26;15(23):5592. doi: 10.3390/cancers15235592. Cancers (Basel). 2023. PMID: 38067296 Free PMC article.
Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients.
Verkhovskaia S, Di Pietro FR, Mastroeni S, Carbone ML, Abeni D, Morese R, Morelli FM, D'Atri S, Marchetti P, De Galitiis F, Failla CM, Fortes C. Verkhovskaia S, et al. Among authors: morelli fm. J Cancer Res Clin Oncol. 2022 Sep;148(9):2529-2538. doi: 10.1007/s00432-021-03811-3. Epub 2021 Sep 30. J Cancer Res Clin Oncol. 2022. PMID: 34595541
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience.
Autore F, Innocenti I, Morelli F, Sorà F, Corbingi A, Fianchi L, Criscuolo M, Pagano L, Sica S, Laurenti L. Autore F, et al. Among authors: morelli f. Hematol Oncol. 2019 Oct;37(4):496-497. doi: 10.1002/hon.2623. Epub 2019 May 30. Hematol Oncol. 2019. PMID: 31017684 Clinical Trial. No abstract available.
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
Tedeschi A, Frustaci AM, Mauro FR, Chiarenza A, Coscia M, Ciolli S, Reda G, Laurenti L, Varettoni M, Murru R, Baratè C, Sportoletti P, Greco A, Borella C, Rossi V, Deodato M, Biagi A, Zamprogna G, Pelle AC, Lapietra G, Vitale C, Morelli F, Cassin R, Fresa A, Cavalloni C, Postorino M, Ielo C, Cairoli R, Di Raimondo F, Montillo M, Del Poeta G. Tedeschi A, et al. Among authors: morelli f. Blood Adv. 2021 Dec 28;5(24):5490-5500. doi: 10.1182/bloodadvances.2021004824. Blood Adv. 2021. PMID: 34525181 Free PMC article.
305 results